Navigation Links
Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron
Post Your Comments:
(Date:9/3/2008)...follow up results from chronically infected Hepati...e data obtained earlier in 2008, - Study is the ...-term antiviral effect of therapeutic Hepat...ngly support move into a second generation, vacci...ting through TLR act...
(Date:9/3/2008)..., Md., Sept. 3 /- Panacea Pharmaceuti...tent Number 7,413,737 covering,antibodies against ...H), a,proprietary human cancer biomarker and thera...collaboration with the Massachusetts Institute of,...ide rights to this patent,for development of human...
(Date:9/3/2008)...ses Operations, Updates Zingo Launch Progress and ...y Conference Call Today at 11:30 ...wswire-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ...e,operations to focus on commercial and late-stage...to a specialty pharmaceutical pain management,comp...
(Date:9/3/2008)...any, Sept. 3 /- A sub-analy...at treatment with prasugrel,compared with clopidog...rent heart attacks (7.4 percent vs. 9.7 percent, p...d around the time of an artery-opening,procedure k...or if they,occurred spontaneously during the longe...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 1Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 2Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 1Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 4Perrigo Announces Approval for Over the Counter Childrens Cetirizine Oral Solution 1763 1Perrigo Announces Approval for Over the Counter Childrens Cetirizine Oral Solution 1763 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 1Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 3Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 4
...007 - CytRx Corporation,(NASDAQ:CYTR), a biopharma...mmercialization of human therapeutics, today,annou... extension,of its completed Phase IIa clinical tri...linical trial was not placebo-controlled,arimoclo... be safe,and well-tolerated throughout the six-mon...
...ganon, the human,healthcare business unit of Akzo ... III clinical trials with corifollitropin alfa,(Or...e reached,their randomization target. , ,Corifoll...e. It is,the first of a new class of gonadotropins...h, due to its long half-life, one single,injection...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
(Date:9/4/2008)...RNewswire/ -- A groundbreaking program,dealing wit... status of,men, their shorter life spans, unmet ge... take place Wednesday, September 17 at White Plain...ers of the Westchester,medical and psychiatric soc....D. and Lionel Tiger, Ph.D., Dr. Legatto, an inte...
(Date:9/4/2008)...ol study, the presence of measles virus RNA was no...bances than in children with only GI disturbances....related to MMR vaccine timing. Study findings are... on September 4 ( http://dx.plos.org/10.1371/jour...n of measles vaccines in 1963, three to four milli...
(Date:9/4/2008)...in and pancreatic tumors , , THURSDAY, S...ing discoveries involving genetic mutations of two...nd pancreatic cancer -- may lead to new treatments...dies represent the most complete genetic analysis ...enetic map of these deadly cancers," Kenneth Kinzl...
(Date:9/4/2008)... are Sold-Out and Sustainable Packaging ...pt. 4 /PRNewswire/ -- The latest innovations in ra...s, and sustainable,packaging will be on full displ...September 9, 10, 11 at the Jacob K. Javits Convent...urals Pavilions at the event are sold-out and,sust...
Breaking Medicine News(10 mins):Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 2Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 3
...ing themselves in a tight corner with finances bei... seek for further Medicaid cuts. The physician acr... in dire consequences for patient care. To add to...cut off $3 billion from the Medicaid program, and ...
...velopment of cancer. Cells without this protein ar...ability would either kill a cell or keep it from g... such a way that they are able to multiply creatin... itself doesn't cause cancer but its absence gives...
...hy women may sometimes be caused by the presence o... after a previous abortion. There were evidence ov...behind after abortion cause chronic irritation whi...octors at the University of Ottawa found that in s...
...ng loss in older people and have found that 25 to ...impaired. Doctors while examining older patients m... remedied. The condition can lead to depression, s...y. There are several reliable tests to detect hear...
Other Medicine News:
Cruciate Retaining, Posterior Stabilized and Constrained Components.
...bilized knee has an advanced design which provides...surfacing and inset patellas. Precision machined c...fit with tibial articular surface and patella to r...rovide easy intraoperative change of sizes. Increa...
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Foundation Knee CR System was designed to replicate normal knee kinematics. The patello- femoral joint has a recessed, deepened and extended patella groove to minimize advancement of the patella,
Medicine Products: